Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells 262,503 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 262,503 shares of Werewolf Therapeutics stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $0.38, for a total transaction of $99,751.14. Following the completion of the sale, the insider directly owned 361,229 shares in the company, valued at approximately $137,267.02. The trade was a 42.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Wednesday, June 10th, Ra Capital Management, L.P. sold 45,923 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.37, for a total value of $16,991.51.
• On Tuesday, June 9th, Ra Capital Management, L.P. sold 369,800 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.37, for a total transaction of $136,826.00.
• On Tuesday, May 12th, Ra Capital Management, L.P. sold 101,151 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $64,736.64.
• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total transaction of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.71, for a total value of $267,333.46.

Werewolf Therapeutics Price Performance

HOWL traded up $0.03 during trading on Thursday, reaching $0.39. 805,388 shares of the stock were exchanged, compared to its average volume of 538,108. The business’s 50 day moving average price is $0.67 and its two-hundred day moving average price is $0.72. The company has a market capitalization of $19.16 million, a price-to-earnings ratio of -0.32 and a beta of 0.29. Werewolf Therapeutics, Inc. has a 1 year low of $0.36 and a 1 year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. On average, analysts anticipate that Werewolf Therapeutics, Inc. will post -1.08 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares during the period. Bank of America Corp DE raised its position in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after purchasing an additional 25,882 shares during the period. Renaissance Technologies LLC raised its position in Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after purchasing an additional 221,766 shares during the period. Jane Street Group LLC purchased a new position in Werewolf Therapeutics in the second quarter valued at about $409,000. Finally, Citadel Advisors LLC purchased a new position in Werewolf Therapeutics in the third quarter valued at about $304,000. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on HOWL shares. Wall Street Zen lowered Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Werewolf Therapeutics has a consensus rating of “Hold” and a consensus target price of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.